Multicenter, Open-label, Safety and Tolerability Study
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This will be a multicenter, 52 week, open label study to assess the safety and tolerability
of oral OPC-34712 (1 to 6 mg) as monotherapy in adult patients with schizophrenia. The study
will be conducted on an outpatient basis. Enrollment into the study will be drawn from
eligible subjects who have completed participation in Study 331-07- 203 and who, in the
investigator's judgment, would benefit from continued treatment with oral OPC-34712.
Phase:
Phase 2
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.